The TGA is investigating the incidence of liver damage associated with the rheumatoid arthritis drug tocilizumab, following adverse events ranging from jaundice to acute hepatic failure.

Tocilizumab (Actemra, Roche) is known to cause transient or intermittent mild to moderate elevation of hepatic transaminases.

In a Medicines Safety Update report, the TGA warns that serious liver injury can occur, although it is rare.

“Patients treated with tocilizumab should be closely monitored for liver adverse events and advised to seek immediate medical advice if they have signs or symptoms of hepatotoxicity such as jaundice, dark urine, itch, loss of appetite, nausea or vomiting,” the TGA says.